exenatide vs semaglutide for T2DM: Key findings and takeaways from 3 major trials GLP-1 Medications for Weight Loss:

The Behavioral Side of Deprescribing Theres clinical language for stopping medication

Several specific types of arrhythmias are frequently associated with heart palpitations

You can read the abstract of this article at In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide demonstrated superior reductions in HbA1c concentrations, bodyweight, and blood pressure compared to titrated daily insulin glargine in individuals with type 2 diabetes and cardiovascular risk

Said differently, theyre designing healthcare coverage around outcomes and not just cost

Rights and permissions About this article Cite this article Bin-Jumah, M., Abdel-Fattah, AF.M., Saied, E.M